ProstACT Global Phase 3 Update: First Patient Administered Treatment in Randomized Expansion, Part 1 Results Schedule Announced

First Patient Dosed: Telix Pharmaceuticals has announced that the first patient has been dosed in Part 2 of its ProstACT Global Phase 3 study, which evaluates TLX591 for metastatic castration-resistant prostate cancer (mCRPC) at the Australian Prostate Centre in Melbourne.

Trial Expansion: The ProstACT Global trial is the first Phase 3 study to combine a PSMA-targeted radio antibody-drug conjugate therapy with standard care, aiming to enroll approximately 490 patients across multiple countries, including Australia, New Zealand, Canada, and plans for expansion into the U.S. and Europe.

Safety Profile: TLX591 is noted for its favorable safety profile, showing minimal kidney toxicity and reduced side effects like dry mouth and dry eyes compared to existing therapies, as it is cleared through the liver.

Company Overview: Telix Pharmaceuticals is focused on developing therapeutic and diagnostic radiopharmaceuticals, with operations in various countries and a commitment to addressing unmet medical needs in oncology and rare diseases.